Vyvanse, or its generic counterpart lisdexamfetamine dimesylate, is prescribed to treat ADHD in adults, and children six years of age or older, as well as moderate to sever binge eating disorder (BED) ...

Becca Stanek is an experienced writer and editor who is passionate about exploring the ways we can feel better mentally and physically to get the most out of our lives. She has worked for publications ...

After 16 years on the market, Takeda's blockbuster attention-deficit/hyperactivity disorder (ADHD) med Vyvanse has finally reached its patent cliff. The med, which is ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved multiple first generics of Vyvanse capsules and chewable tablets for ADHD in patients aged ...

The Food and Drug Administration (FDA) approved the first generic versions of Vyvanse, a drug used to treat attention deficit/hyperactivity disorder (ADHD), a decision that comes amid a nationwide ...

ADHD is an acronym that stands for Attention Deficit Hyperactivity Disorder. It’s a condition that can affect a person’s ability to pay attention, stay focused, and control their impulses. Treatment ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Takeda Pharmaceutical Company ...

Basingstoke, U.K. and Philadelphia, PA – April 23, 2008– Shire plc (LSE: SHP, NASDAQ: SHPGY,), the global specialty biopharmaceutical company, today announced that it has received approval from the ...

WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Friday approved Shire Plc's stimulant Vyvanse to treat binge-eating disorder, the first product to be approved for the condition.